ライフサイエンスコーパス: demyelinate

1 positive for ZIKV infection, 27 had GBS (18 demyelinating, 8 axonal, and 1 Miller Fisher syndrome),

2 ctions in relation to lesion morphometry and demyelinating activity in MS patients.

3 lopment as well as for OPC maturation in the demyelinated adult brain.

4 Following exposure to the demyelinating agent cuprizone, however, GALC +/- animals

5 robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute

6 Multiple sclerosis (MS) is characterized by demyelinated and inflammatory lesions in the brain and s

7 1w/T2w values significantly differed between demyelinated and myelinated cortex (p < 0.001).

8 nnectivity of adult-born neurons between the demyelinated and remyelinated hippocampus, suggesting hi

9 (Cup/Rap) in C57BL/6J male mice efficiently demyelinated and remyelinated the hippocampus, respectiv

10 in both severity and age of onset, including demyelinating and axonal forms of Charcot-Marie Tooth (C

11 the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibo

12 Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the centr

13 Demyelinating and neurodegenerative diseases evoked cont

14 ultiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease affecting t

15 a reduction in inflammatory infiltrates and demyelinated areas in the brains and spinal cords of tre

16 B and the extent of reactive astrogliosis in demyelinating areas and in in vitro assays.

17 sclerosis, but also show that even a single demyelinating attack-when associated with white matter l

18 Of interest to the etiology of demyelinating autoimmune disease is the potential to abe

19 the common forms of either acute or chronic demyelinating autoimmune neuropathy.

20 Multiple sclerosis (MS) is a demyelinating, autoimmune disease of the central nervous

21 logical studies, degeneration of chronically demyelinated axons is not a key feature that distinguish

22 its, which become prevalent at internodes in demyelinated axons, may underlie their dysfunctional con

23 um channels, thereby enhancing conduction in demyelinated axons.

24 n modulate oligodendrocyte maturation in the demyelinated brain and suggest that voltage-gated Ca(2+)

25 he acutely (softer) or chronically (stiffer) demyelinated brain might contribute to differences in th

26 ocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving imm

27 irus from patients with the frequently fatal demyelinating brain disease progressive multifocal leuko

28 This data shows that demyelinating brain lesions are associated with the pres

29 Analysis of mouse and human demyelinated brains indicate that acute demyelination re

30 is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal c

31 Demyelinating central nervous system (CNS) disorders lik

32 morphological parameters in a mouse model of demyelinating CMT1B, without exacerbating the toxic gain

33 mice, OSM overexpression in the chronically demyelinated CNS established remyelination.

34 e the metabolic properties of T cells in the demyelinating CNS in vivo.

35 lls that mediate ongoing inflammation in the demyelinating CNS.

36 nctional deficits underlying diseases with a demyelinating component.

37 an syndrome or Vogt-Koyanagi-Harada disease; demyelinating conditions such as multiple sclerosis or n

38 has been shown to enhance myelination under demyelinating conditions, successfully reversed social a

39 ic relevance in multiple sclerosis and other demyelinating conditions.

40 MOG antibody disease both considered primary demyelinating conditions.

41 tance when understanding myelin assembly and demyelinating conditions.

42 s in the meninges and pronounced in actively demyelinating cortical lesions, retrograde degeneration

43 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established ani

44 hrough the alternative complement cascade in demyelinating disease and identify a strategy to prevent

45 ation abnormalities seen in association with demyelinating disease and optic neuritis, although evide

46 motes recovery from preexisting inflammatory demyelinating disease and suggest that this protection i

47 irmed that NFM was not a critical Ag driving demyelinating disease because NFM18-30-specific T cells

48 unogenic in C57BL/6 mice but fails to induce demyelinating disease by polyclonal T cells despite havi

49 patient who died from a rapidly progressing demyelinating disease known as progressive multifocal le

50 myelin repair in animal models of the human demyelinating disease multiple sclerosis (MS).

51 PCs), thereby impeding remyelination, in the demyelinating disease multiple sclerosis (MS).

52 functional impairment that characterizes the demyelinating disease multiple sclerosis (MS).

53 lination in a preclinical model of the human demyelinating disease multiple sclerosis (MS).IMPORTANCE

54 lation and is the causative agent of a fatal demyelinating disease of the central nervous system (CNS

55 NMOSD is a recently defined demyelinating disease of the central nervous system (CNS

56 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS

57 MS is a chronic idiopathic inflammatory demyelinating disease of the central nervous system (CNS

58 gressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caus

59 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system that

60 Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system trad

61 h multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with

62 ple sclerosis (MS) is known as an autoimmune demyelinating disease of the central nervous system.

63 leukoencephalopathy (PML) is an often-fatal demyelinating disease of the central nervous system.

64 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system.

65 iple sclerosis (MS) is the most common human demyelinating disease of the central nervous system.

66 Centres managing patients with demyelinating disease of the CNS across Australia and Ne

67 nd multiple sclerosis (MS), an inflammatory, demyelinating disease of the CNS of unknown etiology.

68 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS that causes disability

69 ncephalomyelitis is a CD4(+) T cell-mediated demyelinating disease of the CNS that serves as a model

70 e sclerosis (MS), a chronic inflammatory and demyelinating disease of the CNS.

71 T Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

72 tiple sclerosis (MS) is a neuroinflammatory, demyelinating disease of the CNS.

73 Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS.

74 Multiple sclerosis is a chronic, demyelinating disease of the CNS.

75 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS.

76 ultiple Sclerosis (MS) is an immune-mediated demyelinating disease of the human central nervous syste

77 therapeutic modulation of ERK1/2 activity in demyelinating disease or peripheral neuropathies must be

78 -specific virus, causes the aggressive brain-demyelinating disease progressive multifocal leukoenceph

79 e multicentre prospective Canadian Pediatric Demyelinating Disease Study (CPDDS).

80 disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Par

81 hemorrhage, intracranial hemorrhage, spine, demyelinating disease, and epileptic patients.

82 In the 2.3% with demyelinating disease, gabapentin was the most likely se

83 tral nervous system and chronic inflammatory demyelinating disease, providing an experimental animal

84 In glaucoma, which is not considered a demyelinating disease, the observed increase in radial d

85 rimate model of MS, and two rodent models of demyelinating disease, we investigated synapse changes i

86 ven by excessive microglial pruning early in demyelinating disease, which can be rescued by inhibitin

87 lerosis (MS) is a heterogeneous inflammatory demyelinating disease.

88 ultifocal leukoencephalopathy (PML), a fatal demyelinating disease.

89 al leukoencephalopathy (PML), a rare, fatal, demyelinating disease.

90 ler's murine encephalomyelitis virus-induced demyelinating disease.

91 ler's murine encephalomyelitis virus-induced demyelinating disease.

92 lammatory and proliferative genes to promote demyelinating disease.

93 ENT Multiple sclerosis is a severe, chronic, demyelinating disease.

94 ation in OPCs, contributing to Th17-mediated demyelinating disease.

95 rsistence associated with an immune-mediated demyelinating disease.

96 potential therapeutic target for autoimmune demyelinating disease.

97 nic and regulatory roles these cells play in demyelinating disease.

98 spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDD) with a specific biomarker,

99 ors may prove safe and effective in treating demyelinating diseases and potentially other autoimmune

100 ted in the pathogenesis of neuroinflammatory demyelinating diseases as well as enhancement of the mig

101 Treatment against demyelinating diseases has been elusive, partially becau

102 yelin can be replaced after injury or during demyelinating diseases in a regenerative process called

103 al prerequisite for developing therapies for demyelinating diseases in the PNS.

104 s for the application of LRRK2 inhibitors in demyelinating diseases in which oligodendrocyte cell-dea

105 In demyelinating diseases including multiple sclerosis (MS)

106 Progression of demyelinating diseases is caused by an imbalance of two

107 t that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.

108 portant role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), whe

109 reported in patients that recover from acute demyelinating diseases such as Guillain-Barre syndrome.

110 tions including central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS) a

111 therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis (MS).S

112 nstitute clinically debilitating sequelae in demyelinating diseases such as multiple sclerosis, but t

113 axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, cause

114 In demyelinating diseases such as multiple sclerosis, disru

115 loping new therapeutic tools to intervene in demyelinating diseases such as multiple sclerosis.

116 lination underlies the progressive nature of demyelinating diseases such as multiple sclerosis.

117 on's, and amyotrophic lateral sclerosis, and demyelinating diseases such as multiple sclerosis.

118 hat Shp2 is a relevant therapeutic target in demyelinating diseases such as multiple sclerosis.SIGNIF

119 otton rat Sigmodon hispidus For a long time, demyelinating diseases were considered to be autoimmune

120 hich the olfactory system is affected in CNS demyelinating diseases, and raises intriguing questions

121 hat is frequently used to study inflammatory demyelinating diseases, due to increased resistance of t

122 Myelin loss occurring in demyelinating diseases, including multiple sclerosis, is

123 BP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.

124 Because, in demyelinating diseases, the myelin formed during remyeli

125 e significant potential for treating chronic demyelinating diseases.

126 for enhancing remyelination in patients with demyelinating diseases.

127 MAD (pSMAD) 1/5/8 in lesions of MS and other demyelinating diseases.

128 development in multiple sclerosis and other demyelinating diseases.

129 his pool of progenitors to replace myelin in demyelinating diseases.

130 mportant role in the pathogenesis underlying demyelinating diseases.

131 xonal degeneration that occurs in peripheral demyelinating diseases.

132 nd development of regenerative therapies for demyelinating diseases.

133 for therapeutic targeting of LSDs and other demyelinating diseases.

134 t enhance remyelination in patients with CNS demyelinating diseases.

135 inflammation and promote myelin recovery in demyelinating diseases.SIGNIFICANCE STATEMENT Reducing v

136 ising strategies to advance the treatment of demyelinating diseases.SIGNIFICANCE STATEMENT The benefi

137 kodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lys

138 Multiple Sclerosis (MS) is an inflammatory demyelinating disorder in which remyelination failure co

139 ic oligodendrocyte loss, which occurs in the demyelinating disorder multiple sclerosis (MS), contribu

140 Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CN

141 Multiple sclerosis is an autoimmune demyelinating disorder of the CNS, characterized by infl

142 Multiple sclerosis is a chronic autoimmune demyelinating disorder of the CNS.

143 Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS.

144 d disease (MOG-AAD) is a recently recognized demyelinating disorder predominantly affecting children

145 effective remyelination in the treatment of demyelinating disorders and in identifying pathways invo

146 of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS.

147 ay be a therapeutically tractable target for demyelinating disorders of the CNS.SIGNIFICANCE STATEMEN

148 disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel dis

149 nation.SIGNIFICANCE STATEMENT Myelin loss in demyelinating disorders such as multiple sclerosis resul

150 evelopment of therapies to promote repair in demyelinating disorders such as multiple sclerosis.

151 ompensate myelin loss in the early phases of demyelinating disorders, this spontaneous reparative pot

152 nisms sustaining endogenous remyelination in demyelinating disorders, we focused our attention on end

153 ation between HSV-1 infection and multifocal demyelinating disorders.

154 vaccination against HSV-1 can help to combat demyelinating disorders.

155 enues for treatment of neurodegenerative and demyelinating disorders.

156 ons, but also provide potential insight into demyelinating disorders.

157 tion contributes to remyelination failure in demyelinating disorders.

158 rapeutic potential to boost remyelination in demyelinating disorders.

159 ged myelin deteriorates during the course of demyelinating disorders.

160 accination against HSV-1 may protect against demyelinating disorders.IMPORTANCE Our work demonstrates

161 The resultant phenotype is severe demyelinating DSN with onset at two years of age, confir

162 nflammatory neuropathy with mixed axonal and demyelinating electrophysiology.

163 ole of cholesterol in promoting repair after demyelinating episodes.

164 reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated

165 Early treatment following a first clinical demyelinating event (FCDE) delays further disease activi

166 Study with 127 cases having a classic first demyelinating event followed for 5 years from onset.

167 und to attenuate the conversion from a first demyelinating event to clinically definite MS in a phase

168 rsion in individuals experiencing an initial demyelinating event.

169 y, we evaluated the role of CRYAB in primary demyelinating events.

170 in g-ratios, myelin thickness, and ratios of demyelinated fibres in lumbar roots and sciatic nerves o

171 on of NCS can be difficult and none of these demyelinating findings are specific for CIDP.

172 to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in re

173 gical tests were consistent with the primary demyelinating form of the disease.

174 opathy with liability to pressure palsies or demyelinating forms of Charcot-Marie-Tooth disease.

175 In the demyelinated hippocampus, neurogenesis was nearly absent

176 e dramatically decreased neurogenesis in the demyelinated hippocampus.

177 tate to a mitotically-quiescent state in the demyelinated hippocampus.

178 ocytes within regions previously shown to be demyelinated in later stages of this syndrome.

179 isease type 4C and potentially other similar demyelinating inherited neuropathies.

180 icroglial subtypes were also found following demyelinating injury in mice, at least one of which was

181 yelinating drug for the treatment of chronic demyelinating injury in multiple sclerosis.

182 into Gamt-deficient and wild-type mice with demyelinating injury reduced oligodendrocyte apoptosis,

183 Using lysolecithin-induced demyelinating injury to the mouse spinal cord, we charac

184 timed motor learning improves recovery from demyelinating injury via enhanced remyelination from new

185 rs myelin production and remyelination after demyelinating injury.

186 human white matter injury from normal rodent demyelinating injury.

187 hormone (T3)-free window, with or without a demyelinating insult, provides a favorable environment f

188 earance and diminished remyelination after a demyelinating insult.

189 roptotic, and apoptotic cell death caused by demyelinating, ischemic, and traumatic injuries, implyin

190 n the remyelination of a focal, lysolecithin-demyelinated lesion in adult male mice.

191 ultiple sclerosis patient lymphocytes in the demyelinated lesion of nude mice spinal cord.

192 iple sclerosis pathology outside the classic demyelinating lesion.

193 etrograde degeneration was mainly related to demyelinated lesions and axonal loss in the white matter

194 r study suggests that mature OLG surrounding demyelinated lesions are not passive witnesses but contr

195 The repair of inflamed, demyelinated lesions as in multiple sclerosis (MS) neces

196 Many chronically demyelinated lesions have oligodendrocyte progenitor cel

197 ectin aggregate containing cuprizone-induced demyelinated lesions in male mice.

198 utes to altered progenitor cell functions in demyelinated lesions in MS.

199 be used as a PET tracer for the detection of demyelinated lesions in rodent models of MS.

200 oitin sulfate proteoglycan deposition around demyelinated lesions in the spinal cord of Theiler's mur

201 s CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler's mur

202 Focal demyelinated lesions in the white matter occurred at sit

203 Subependymal demyelinated lesions with axonal loss and microglial/mac

204 T1-hypointense, and appeared as perivascular demyelinated lesions with dystrophic neurons/axons.

205 on of sterol synthesis boosted the repair of demyelinated lesions, suggesting novel therapeutic strat

206 we investigate the contributions of thalamic demyelinated lesions, thalamic neuronal loss, and cerebr

207 eloid cell population at the edge of chronic demyelinated lesions.

208 nd restoration of function through repair of demyelinated lesions.

209 macrophages determines the repair of acutely demyelinated lesions.

210 ally involved in the formation and repair of demyelinated lesions.

211 All presented with cerebral demyelinating lesions and gadolinium enhancement.

212 Cortical demyelinating lesions are clinically important in multip

213 Here, we developed a method to label CNS demyelinating lesions by the intraperitoneal injection o

214 S autoimmunity characterized by inflammatory demyelinating lesions confined to optic nerves and spina

215 sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environme

216 Demyelinating lesions were not centered on the injection

217 early axonal pathology outside inflammatory demyelinating lesions.

218 ntributors to thalamic atrophy than thalamic demyelinating lesions.

219 associated inflammation and the formation of demyelinating lesions.

220 stored in remyelinated, but not persistently demyelinated, lesions.

221 pipelines we were able to: (1) Discriminate demyelinating macrophages from the resident microglial p

222 ct proline dyad in the FP of the recombinant demyelinating MHV strain plays a crucial role in translo

223 ting a single proline residue in the FP of a demyelinating MHV strain, we found that two central, con

224 reated with Inh X migrate extensively in the demyelinated mouse spinal cord and remyelinate axons.

225 form in vivo fate-tracing in an inflammatory demyelinating mouse model.

226 In human demyelinated MS brain lesions, but not normal appearing

227 s of DNA methyltransferase were increased in demyelinated MS hippocampus, while de-methylation enzyme

228 6 genes and hyper-methylation of 10 genes in demyelinated MS hippocampus.

229 The presence of myelinosomes in actively demyelinating MS lesions suggests that oligodendrocyte d

230 ially phosphorylated in astrocytes in active demyelinating MS lesions, as well as in cuprizone-induce

231 %) loss of anterior horn neurons, notably in demyelinating MS lesions.

232 ogen and the BMP target Id2 are increased in demyelinated multiple sclerosis (MS) lesions.

233 TIMP-1 was expressed by human astrocytes in demyelinated multiple sclerosis lesions, confirming the

234 , implicating c-Jun as a potential player in demyelinating neuropathies.

235 ses myelin genes, and has been implicated in demyelinating neuropathies.

236 e axonal degeneration observed in peripheral demyelinating neuropathies.

237 ifically whether MMN represents an axonal or demyelinating neuropathy and whether the underlying path

238 The OGT-SCKO mice develop tomaculous demyelinating neuropathy characterized by focal thickeni

239 B (CMT1B) neuropathy in humans and a similar demyelinating neuropathy in transgenic mice, is instead

240 opsy showed a mixed predominantly axonal and demyelinating neuropathy in two sCJDMV2K.

241 tory VEGF testing for patients with acquired demyelinating neuropathy is a cost-effective strategy al

242 common form of hereditary autosomal dominant demyelinating neuropathy known as Charcot-Marie-Tooth di

243 4C is the most common recessively inherited demyelinating neuropathy that results from loss of funct

244 ts with recurrent acute predominantly motor, demyelinating neuropathy with conduction block, and chro

245 for patients with acute predominantly motor, demyelinating neuropathy with conduction block, and seco

246 Testing patients with acquired demyelinating neuropathy with serum vascular endothelial

247 tory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savin

248 ch difficulties) and peripheral (early onset demyelinating neuropathy) neurological involvement, who

249 1X), one of the commonest forms of inherited demyelinating neuropathy, results from GJB1 gene mutatio

250 GF testing for all patients with an acquired demyelinating neuropathy.

251 experimental optic neuritis, an inflammatory demyelinating optic nerve condition that occurs in MS an

252 Demyelinating optic nerve inflammation, termed optic neu

253 R hypersignal was not related to ischemic or demyelinating optic nerve pathology but was associated w

254 Acute demyelinating optic neuritis, a common feature of multip

255 th relapsing multiple sclerosis with chronic demyelinating optic neuropathy on stable immunomodulator

256 Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% an

257 on with implications in axonal repair in CNS demyelinating pathologies.SIGNIFICANCE STATEMENT The dep

258 Inherited demyelinating peripheral neuropathies are progressive in

259 a potential opportunity for the treatment of demyelinating peripheral neuropathies.

260 ie-Tooth disease type 4B1 (CMT4B1), a severe demyelinating peripheral neuropathy characterized by mye

261 aged Prnp(ZH3/ZH3) mice developed a chronic demyelinating peripheral neuropathy, confirming the cruc

262 lly authentic model of CMT1X that develops a demyelinating peripheral neuropathy.

263 providing robust evidence that the profound demyelinating phenotype observed in the dorsal columns o

264 of a group of MOG-Ab-positive patients with demyelinating phenotypes.

265 nd less frequently in the acute inflammatory demyelinating polyneuropathy (AIDP) type of GBS or in ce

266 The association between chronic inflammatory demyelinating polyneuropathy (CIDP) and diabetes is unce

267 ar clinical features of chronic inflammatory demyelinating polyneuropathy (CIDP) except 'motor neurop

268 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediate

269 thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intra

270 in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP).

271 were consistent with the acute inflammatory demyelinating polyneuropathy subtype of the Guillain-Bar

272 ropathy and variants of chronic inflammatory demyelinating polyneuropathy, account for a proportion o

273 past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren's syndrome, and sy

274 rse myelitis, and 1 had chronic inflammatory demyelinating polyneuropathy.

275 %) with newly diagnosed chronic inflammatory demyelinating polyneuropathy.

276 Peripheral neuropathies included axonal and demyelinating polyradiculoneuropathies (n = 2), length-d

277 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consists of

278 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare an

279 orrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

280 e fibre types including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP: N=20); amylo

281 ssel-wall fibrosis was detected early in the demyelinating process, even in lesions <2 weeks old, tho

282 Because the pathogenicity and demyelinating properties of anti-MAG autoantibodies are

283 onstrate that administration of tamoxifen to demyelinated rats in vivo accelerates remyelination.

284 utoreactive T-cell and microglial/macrophage demyelinating response is critical to effectively target

285 pical' subtypes, such as multifocal acquired demyelinating sensory and motor neuropathy (Lewis-Sumner

286 Applying lysolecithin-induced focal demyelinating spinal cord lesions, we found that FA synt

287 tive immune responses as well as the chronic demyelinating stage of disease in response to JHMV infec

288 (Lewis-Sumner syndrome) and 'distal acquired demyelinating symmetric neuropathy', possibly having dif

289 ssigned participants who had had their first demyelinating symptoms within the previous 180 days to r

290 Most children who experience an acquired demyelinating syndrome of the central nervous system wil

291 1, 2013, and Dec 31, 2018, 239 children with demyelinating syndromes (cohort A) and 296 with encephal

292 QP4-IgG-negative optic neuritis (n=4), other demyelinating syndromes (n=3) and multiple sclerosis (n=

293 wider than previously reported and includes demyelinating syndromes and encephalitis.

294 ospective observational study, children with demyelinating syndromes and with encephalitis other than

295 Atypical inflammatory demyelinating syndromes are rare disorders that differ f

296 Fifty-three participants with demyelinating syndromes eventually received a diagnosis

297 of 132 paediatric participants with acquired demyelinating syndromes followed for a median of 4.4 yea

298 tence of sexual dimorphism in the effects of demyelinating syndromes on normal-appearing white matter

299 tein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG

300 to perform micro-indentation measurements of demyelinated tissue at cellular scale.